47P Phase I study to assess the safety and efficacy of P-BCMA-ALLO1: A fully allogeneic CAR-T therapy, in patients with relapsed/refractory multiple myeloma (RRMM). (December 2022) - Kocoglu, M.H.; Asch, A.; Ramakrishnan, A.; Bachier, C.; Martin, T.; Rodriguez, T.; McArthur, K.; Martin, C.; Namini, H.; Ostertag, E.; Spear, M.; Christie, E.; et al.